Infrequent epigenetic dysregulation of CIP/KIP family of cyclin-dependent kinase inhibitors in multiple myeloma Leukemia (2005) Cell cycle progression is triggered by the activation of cyclindependent kinase 4/6 (CDK 4/6 ) upon binding of cyclin D, and further potentiated by subsequent activation of CDK 2 . On the other hand, the cell cycle is negatively regulated by the INK4 (p15, p16, p18 and p19) and the CIP/KIP (p21 CIP , p27 KIP1 and p57 KIP2 ) families of cyclin-dependent kinase inhibitors (CKI). 1 The INK4 family of CKIs bind to and inhibit CDK 4/6 .
2 By contrast, the CKIs of the CIP/KIP family may bind to both CDK 2 and CDK 4/6 , and modulate their kinase activities. In quiescent cells, CIP/KIP CKIs bind to and inhibit the activity of CDK 2 , resulting in cell cycle arrest. In cycling cells, CKIs of the CIP/KIP TTG GGC GCG GAT TCG TC  CTA AAC CGC CGA CCC GA  631C/35  U-MSP  TTA GTT TTT TGT GGA GTT G  CTC AAC TCT AAA CCA CAA   p27  M-MSP  AAG AGG CGA GTT AGC GT  AAA ACG CCG CCG AAC GA  651C/35  U-MSP  ATG GAA GAG GTG AGT TAG T  AAA ACC CCA ATT AAA ACA   p57  M-MSP  CGC GGT CGT TAA TTA GTC GC  ACA CAA CGC ACT TAA CCT ATA A  641C/35  U-MSP  TTT GTT TTG TGG TTG TTA ATT AGT TGT  ACA CAA CGC ACT TAA CCT ATA A T m : annealing temperature; M-MSP: methylation-specific polymerase chain reaction for the methylated allele; U-MSP: MSP for the unmethylated allele. family detach from CDK 2 /cyclin E complex and bind to CDK 4/6 instead, resulting in derepression (and thus activation) of CDK 2 and further activation of CDK 4/6 , resulting in commitment of the cell to transit the G 1 S cell cycle checkpoint. 1 The p21 CIP1/WAF1/CDKN1A is a tumour suppressor gene inducible by wild-type p53 in the presence of DNA damage, leading to cell cycle arrest at the G 1 S checkpoint. Its tumor suppressor function is illustrated by the development of a variety of tumours, including sarcomas and lymphomas in p21 knockout mice.
2 p27 KIP1/CDKN1B is a haplo-insufficient tumour suppressor, as p27 haplo-insufficient mice are hypersensitive to carcinogens. 2 On the other hand, p57 KIP2/CDKN1C is a paternally imprinted, maternally expressed CKI targeting cyclin A/CDK2 complex. 2 The tumor suppressor role of p27 and p57 is demonstrated by the low expression of these two genes in multiple human cancers. 2 However, apart from patients with Beckwith-Wiedemann syndrome, mutation of p57 in human cancers is rare, suggesting an alternative mechanism of gene inactivation. 2 DNA methylation, catalysed by DNA methyltransferase, involves the addition of a methyl group to the carbon 5 position of the cytosine ring in the CpG dinucleotide, converting it to methylcytosine. 3 In many cancers, the CpG islands of selected genes are aberrantly methylated (hypermethylated), resulting in transcriptional repression. This may serve as an alternative mechanism of gene inactivation.
Epigenetic dysregulation of the INK4 CKI/cyclin D/RB cell cycle control pathway has been demonstrated in multiple myeloma (MM) 4 Here, we investigated the role of methylation of the CIP/KIP family of CKI in MM.
Diagnostic The methylation-specific polymerase chain reaction (MSP) for gene promoter methylation was performed as described previously. 5 Treatment of DNA with bisuphite for conversion of unmethylated cytosine to uracil (but unaffecting methylated cytosine) was performed with a commercially available kit (CpGenome DNA modification kit, Intergen, New York, USA). The primers for the methylated (M-MSP) and unmethylated (U-MSP) promoters of p21, p27 and p57 was shown in Table 1 . DNA from 10 normal donors were used as negative control, while methylated control DNA (CpGenome Universal Methylated NA, Intergen) was used as positive control in all the experiments. MSP was performed in a thermal cycler (9600, PE Biosystems, Foster City, CA, USA) with the following cycling conditions: 951C for 4 min; 35 cycles of 951C for 45 s, specific annealing temperature for 30 s, and 721C for 30 s; and a final extension of 10 min at 721C. The PCR mixture contained 50 ng of bisulphite treated DNA, 0.2 mM dNTPs, 2 mM MgCl 2 , 10 pmol of each primer, 1 Â PCR buffer and 2.5 U of FastStart Taq DNA Polymerase (Roche Diagnostics) in a final volume of 50 ml. PCR products (10 ml) were loaded onto 6% nondenaturing polyacrylamide gels, electrophoresed, and visualized under ultraviolet light after staining with ethidium bromide. For RT-PCR of p57, 1 mg of total cellular RNA was reverse-transcribed with M-MLV reverse transcriptase (Life Technologies Inc., Rockville, MD, USA) and 2 ml of the resulted single-stranded cDNA was amplified by PCR at an annealing temperature of 651C for 35 cycles with p57-specific RT-PCR primers: 5 0 -CTGATCTCC GATTTCTTCGC-3 0 (sense) and 5 0 -TCTTTGGGCTCTAAATTGG-3 0 (antisense). The human myeloma cell line WL2 was cultured in RPMI supplemented with 10% fetal calf serum. 5 For treatment with 5-AC, WL2 cells were seeded in a six-well plate at a density of 10 6 cells/ml, and cultured with 5 mM of 5-azacytidine (5-AC) (Sigma, St Louis, MO, USA) for 5 days, with fresh medium containing 5-AC replenished every 2 days. 5-AC treated WL2 cells on day 0 and day 5 were harvested for genomic DNA and total cellular RNA extractions.
None of the three genes tested was methylated in the 10 normal marrow control samples. p21 and p27 were completely unmethylated in all cell lines (Figure 1) . p57 was completely methylated in WL2 but unmethylated in other five cell lines (Figure 1) . 5-AC treatment of WL2 cell line resulted in demethylation of p57 as evidenced by the emergence of the U-MSP amplification and reappearance of p57 transcript on day 5, compared with the completely methylated status and the absence of p57 transcript on day 0 (Figure 2 ). In the primary myeloma samples, three of 55 (5.5%) patients had p57 methylation but none had p21 and p27 methylation (Figure 1) .
We demonstrated the absence of p21 methylation in all primary myeloma samples, consistent with the absence of p21 methylation in hematological malignancies. 6 Moreover, as mutation and deletion of p21 are rare in human cancers, 7 p21 does not pose a target of gene inactivation.
p27 methylation was absent in our myeloma patients. As p27 mutation and deletion are rare in hematological cancers, 8 p27 does not appear to be a target of gene inactivation. However, 'functional inactivation' of p27 may be mediated by the phosphorylation of the nuclear localisation domain, resulting in the cytoplasmic mislocalisation of p27, thereby precluding p27 5-AC treatment of WL2 cell line for 5 days. P57 was completely unmethylated in the normal marrow control, which was associated with constitutive expression of p57 transcript in normal marrow cells. On day 0, untreated WL2 was completely methylated for p57 with absence of p57 transcript. 5-AC treatment of WL2 cell line resulted in demethylation of DAP kinase as evidenced by the emergence of the U-MSP amplification of DAP kinase and appearance of DAP kinase transcript on day 5. MW: marker; B: reagent blank; D0: day 0; D5: day 5 culture with 5 mM 5-AC; NC: normal marrow control; PC: positive control. from its regulation of CDK 2 in the nucleus. 9 Therefore, the role of p27 in the pathogenesis of myeloma requires further study.
Lastly, the infrequent p57 methylation in patients with MM is similar to another study, which showed p57 methylation in only four (15.4%) of 26 myeloma patients. 10 Moreover, gene silencing associated with methylation was demonstrated in WL2 cell line, in which demethylation led to re-expression of p57 transcript.
In conclusion, in contrast to frequent methylation of p15 and p16, both CKI members of the INK4 family, we showed the absence of p21 and p27 methylation and infrequent p57 methylation in 55 patients with MM. This is also consistent with the absence of p21 and p27 methylation, and the infrequent methylation of p57 in myeloma cell lines. Our data suggested that epigenetic dysregulation of the INK4 family, instead of the CIP/KIP family of CKI, is the predominant mechanism to abrogate negative regulation of the G 1 S cell cycle control in MM. This is consistent with recent data showing an essential role of CDK4 but not CDK2 in cell proliferation. 1 FLT3 mutations are common in acute myeloid leukaemia (AML), most often an internal tandem duplication (itd), and are associated with a poor prognosis.
1-6 FLT3-itd mutations can be detected by PCR of genomic DNA. 1, 3 Some patients show excess dosage of the FLT3-itd allele, or apparent complete loss of the FLT3 wild-type (wt) gene, [1] [2] [3] [4] [5] [6] and this has been associated with a more adverse prognosis. [3] [4] [5] The mechanism for excess dosage is not known, although cryptic deletions of the FLT3-wt region, 3, 4 acquired isodisomy (AI) for chromosome 13, 4 or segmental AI through homologous somatic recombination, 5 have been suggested. This uncertainty with respect to the mechanism confounds analysis of prognostic impact within this potential subgroup of FLT3-itd patients as stratification without knowledge of the mechanism may be inaccurate. We investigated these mechanisms and demonstrated AI for chromosome 13 (AI-13) to be the most likely cause of FLT3-itd excess dosage.
In all, 148 consecutive confirmed AML patients, at diagnosis (144) or relapse (four), with normal karyotypes were investigated at two centres. DNA was extracted using Puregene kits (Gentra Systems, Minneapolis, USA) from fresh samples; or from fixed (3:1 methanol:acetic acid) cytogenetic cell pellets using a modified standard phenol/chloroform extraction. FLT3-itd status was determined by semi-quantitative PCR of genomic DNA using published primers 3 for exons 14 and 15 and the intervening intron, 7 with fragment sizing on a fluorescent capillary sequencer (Beckman Coulter CEQ8000 or Applied Biosystems 3100). Selected patients were analysed for variation in allele dosage of short tandem repeat (STR) DNA microsatellite markers on chromosome 13 by PCR and fragment sizing on a Beckman CEQ8000 using a modified QF-PCR protocol.
8 FLT3-itd mutations were identified in 51/148 (34%) patients, with 8/51 (16% of FLT3-itd cases) having a FLT3-itd to FLT3-wt ratio greater than 1, implying increased copy number for FLT3-itd or decreased copy number for the FLT3-wt (Figure 1) . Brief clinical
